View Financial HealthMicroBase Technology 배당 및 자사주 매입배당 기준 점검 0/6MicroBase Technology 배당금을 지급한 기록이 없습니다.핵심 정보0%배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향0%최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updatesValuation Update With 7 Day Price Move • May 20Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to NT$25.00, the stock trades at a trailing P/E ratio of 52.3x. Average trailing P/E is 19x in the Medical Equipment industry in Taiwan. Total returns to shareholders of 19% over the past three years.New Risk • May 05New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 14% Last year net profit margin: 32% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (20% average weekly change). Minor Risks Profit margins are more than 30% lower than last year (14% net profit margin). Market cap is less than US$100m (NT$1.48b market cap, or US$46.9m).Valuation Update With 7 Day Price Move • Apr 23Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to NT$16.60, the stock trades at a trailing P/E ratio of 21.9x. Average trailing P/E is 19x in the Medical Equipment industry in Taiwan. Total loss to shareholders of 15% over the past three years.공시 • Apr 02MicroBase Technology Corp., Annual General Meeting, Jun 25, 2026MicroBase Technology Corp., Annual General Meeting, Jun 25, 2026. Location: no,756, ch`ieh tung rd., bade district, taoyuan city TaiwanValuation Update With 7 Day Price Move • Apr 01Investor sentiment improves as stock rises 38%After last week's 38% share price gain to NT$19.70, the stock trades at a trailing P/E ratio of 26x. Average trailing P/E is 18x in the Medical Equipment industry in Taiwan. Total loss to shareholders of 5.9% over the past three years.Valuation Update With 7 Day Price Move • Mar 16Investor sentiment improves as stock rises 24%After last week's 24% share price gain to NT$14.05, the stock trades at a trailing P/E ratio of 18.5x. Average trailing P/E is 19x in the Medical Equipment industry in Taiwan. Total loss to shareholders of 34% over the past three years.New Risk • Mar 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (NT$788.4m market cap, or US$25.1m).New Risk • Feb 11New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 9.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.9% average weekly change). Minor Risk Market cap is less than US$100m (NT$750.6m market cap, or US$23.9m).Valuation Update With 7 Day Price Move • Feb 11Investor sentiment improves as stock rises 25%After last week's 25% share price gain to NT$11.85, the stock trades at a trailing P/E ratio of 15.6x. Average trailing P/E is 19x in the Medical Equipment industry in Taiwan. Total loss to shareholders of 34% over the past three years.New Risk • Aug 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.1% average weekly change). Market cap is less than US$100m (NT$842.9m market cap, or US$28.2m).Reported Earnings • Apr 26Full year 2024 earnings released: EPS: NT$0.86 (vs NT$0.47 in FY 2023)Full year 2024 results: EPS: NT$0.86 (up from NT$0.47 in FY 2023). Revenue: NT$214.8m (up 10% from FY 2023). Net income: NT$69.4m (up 82% from FY 2023). Profit margin: 32% (up from 20% in FY 2023). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 107% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Apr 16Investor sentiment improves as stock rises 16%After last week's 16% share price gain to NT$10.45, the stock trades at a trailing P/E ratio of 13.1x. Average trailing P/E is 19x in the Medical Equipment industry in Taiwan. Total loss to shareholders of 17% over the past three years.Buy Or Sell Opportunity • Apr 14Now 21% overvaluedOver the last 90 days, the stock has fallen 17% to NT$10.15. The fair value is estimated to be NT$8.41, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 3.3% over the last 3 years. Meanwhile, the company has become profitable.공시 • Apr 02MicroBase Technology Corp., Annual General Meeting, Jun 26, 2025MicroBase Technology Corp., Annual General Meeting, Jun 26, 2025. Location: no,756, ch`ieh tung rd., bade district, taoyuan city TaiwanBuy Or Sell Opportunity • Mar 28Now 22% overvaluedOver the last 90 days, the stock has fallen 23% to NT$10.40. The fair value is estimated to be NT$8.56, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 3.3% over the last 3 years. Meanwhile, the company has become profitable.New Risk • Feb 28New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (NT$951.3m market cap, or US$28.9m).New Risk • Dec 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.6% average weekly change). Market cap is less than US$100m (NT$1.12b market cap, or US$34.3m).Valuation Update With 7 Day Price Move • Dec 23Investor sentiment improves as stock rises 17%After last week's 17% share price gain to NT$13.85, the stock trades at a trailing P/E ratio of 17.3x. Average trailing P/E is 18x in the Medical Equipment industry in Taiwan. Total loss to shareholders of 5.1% over the past three years.Reported Earnings • Apr 12Full year 2023 earnings released: EPS: NT$0.48 (vs NT$0.079 in FY 2022)Full year 2023 results: EPS: NT$0.48 (up from NT$0.079 in FY 2022). Revenue: NT$194.8m (up 6.8% from FY 2022). Net income: NT$38.1m (up 500% from FY 2022). Profit margin: 20% (up from 3.5% in FY 2022). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 108% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.공시 • Apr 03MicroBase Technology Corp., Annual General Meeting, Jun 24, 2024MicroBase Technology Corp., Annual General Meeting, Jun 24, 2024.New Risk • Mar 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.6% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (NT$1.01b market cap, or US$31.8m).New Risk • Aug 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (8.9% average weekly change). Minor Risk Market cap is less than US$100m (NT$1.12b market cap, or US$35.3m).Reported Earnings • Apr 01Full year 2022 earnings released: EPS: NT$0.08 (vs NT$0.47 loss in FY 2021)Full year 2022 results: EPS: NT$0.08 (up from NT$0.47 loss in FY 2021). Revenue: NT$182.3m (down 14% from FY 2021). Net income: NT$6.35m (up NT$43.7m from FY 2021). Profit margin: 3.5% (up from net loss in FY 2021). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • Aug 15First half 2022 earnings released: NT$0.03 loss per share (vs NT$0.11 loss in 1H 2021)First half 2022 results: NT$0.03 loss per share (up from NT$0.11 loss in 1H 2021). Revenue: NT$82.9m (down 26% from 1H 2021). Net loss: NT$2.17m (loss narrowed 75% from 1H 2021). Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 13% per year.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • Aug 18First half 2021 earnings released: NT$0.11 loss per share (vs NT$0.41 loss in 1H 2020)The company reported a decent first half result with reduced losses and improved control over expenses, although revenues were weaker. First half 2021 results: Revenue: NT$111.6m (down 9.0% from 1H 2020). Net loss: NT$8.84m (loss narrowed 71% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.분석 기사 • Apr 11Is MicroBase Technology (GTSM:3184) Using Debt In A Risky Way?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Reported Earnings • Apr 11Full year 2020 earnings released: NT$0.95 loss per share (vs NT$0.75 loss in FY 2019)The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: NT$249.8m (down 5.9% from FY 2019). Net loss: NT$74.0m (loss widened 51% from FY 2019). Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Feb 01New 90-day low: NT$12.75The company is down 34% from its price of NT$19.45 on 03 November 2020. The Taiwanese market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 26% over the same period.Is New 90 Day High Low • Jan 15New 90-day low: NT$14.70The company is down 25% from its price of NT$19.50 on 16 October 2020. The Taiwanese market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 29% over the same period.Is New 90 Day High Low • Dec 22New 90-day low: NT$16.20The company is down 16% from its price of NT$19.40 on 24 September 2020. The Taiwanese market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 13% over the same period.Is New 90 Day High Low • Dec 05New 90-day low: NT$17.45The company is down 9.0% from its price of NT$19.10 on 04 September 2020. The Taiwanese market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 9.0% over the same period.분석 기사 • Dec 01Is MicroBase Technology (GTSM:3184) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Is New 90 Day High Low • Nov 06New 90-day low: NT$18.90The company is down 8.0% from its price of NT$20.55 on 07 August 2020. The Taiwanese market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is down 4.0% over the same period.Is New 90 Day High Low • Sep 22New 90-day low: NT$19.00The company is down 7.0% from its price of NT$20.50 on 24 June 2020. The Taiwanese market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 2.0% over the same period.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 3184 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: 3184 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장MicroBase Technology 배당 수익률 vs 시장3184의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (3184)0%시장 하위 25% (TW)1.4%시장 상위 25% (TW)5.0%업계 평균 (Medical Equipment)3.8%분석가 예측 (3184) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 3184 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 3184 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 3184 TW 시장에서 주목할만한 배당금을 지급하지 않습니다.주주 현금 배당현금 흐름 범위: 3184 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YTW 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/26 22:16종가2026/05/26 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스MicroBase Technology Corp.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Valuation Update With 7 Day Price Move • May 20Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to NT$25.00, the stock trades at a trailing P/E ratio of 52.3x. Average trailing P/E is 19x in the Medical Equipment industry in Taiwan. Total returns to shareholders of 19% over the past three years.
New Risk • May 05New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 14% Last year net profit margin: 32% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (20% average weekly change). Minor Risks Profit margins are more than 30% lower than last year (14% net profit margin). Market cap is less than US$100m (NT$1.48b market cap, or US$46.9m).
Valuation Update With 7 Day Price Move • Apr 23Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to NT$16.60, the stock trades at a trailing P/E ratio of 21.9x. Average trailing P/E is 19x in the Medical Equipment industry in Taiwan. Total loss to shareholders of 15% over the past three years.
공시 • Apr 02MicroBase Technology Corp., Annual General Meeting, Jun 25, 2026MicroBase Technology Corp., Annual General Meeting, Jun 25, 2026. Location: no,756, ch`ieh tung rd., bade district, taoyuan city Taiwan
Valuation Update With 7 Day Price Move • Apr 01Investor sentiment improves as stock rises 38%After last week's 38% share price gain to NT$19.70, the stock trades at a trailing P/E ratio of 26x. Average trailing P/E is 18x in the Medical Equipment industry in Taiwan. Total loss to shareholders of 5.9% over the past three years.
Valuation Update With 7 Day Price Move • Mar 16Investor sentiment improves as stock rises 24%After last week's 24% share price gain to NT$14.05, the stock trades at a trailing P/E ratio of 18.5x. Average trailing P/E is 19x in the Medical Equipment industry in Taiwan. Total loss to shareholders of 34% over the past three years.
New Risk • Mar 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (NT$788.4m market cap, or US$25.1m).
New Risk • Feb 11New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 9.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.9% average weekly change). Minor Risk Market cap is less than US$100m (NT$750.6m market cap, or US$23.9m).
Valuation Update With 7 Day Price Move • Feb 11Investor sentiment improves as stock rises 25%After last week's 25% share price gain to NT$11.85, the stock trades at a trailing P/E ratio of 15.6x. Average trailing P/E is 19x in the Medical Equipment industry in Taiwan. Total loss to shareholders of 34% over the past three years.
New Risk • Aug 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.1% average weekly change). Market cap is less than US$100m (NT$842.9m market cap, or US$28.2m).
Reported Earnings • Apr 26Full year 2024 earnings released: EPS: NT$0.86 (vs NT$0.47 in FY 2023)Full year 2024 results: EPS: NT$0.86 (up from NT$0.47 in FY 2023). Revenue: NT$214.8m (up 10% from FY 2023). Net income: NT$69.4m (up 82% from FY 2023). Profit margin: 32% (up from 20% in FY 2023). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 107% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Apr 16Investor sentiment improves as stock rises 16%After last week's 16% share price gain to NT$10.45, the stock trades at a trailing P/E ratio of 13.1x. Average trailing P/E is 19x in the Medical Equipment industry in Taiwan. Total loss to shareholders of 17% over the past three years.
Buy Or Sell Opportunity • Apr 14Now 21% overvaluedOver the last 90 days, the stock has fallen 17% to NT$10.15. The fair value is estimated to be NT$8.41, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 3.3% over the last 3 years. Meanwhile, the company has become profitable.
공시 • Apr 02MicroBase Technology Corp., Annual General Meeting, Jun 26, 2025MicroBase Technology Corp., Annual General Meeting, Jun 26, 2025. Location: no,756, ch`ieh tung rd., bade district, taoyuan city Taiwan
Buy Or Sell Opportunity • Mar 28Now 22% overvaluedOver the last 90 days, the stock has fallen 23% to NT$10.40. The fair value is estimated to be NT$8.56, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 3.3% over the last 3 years. Meanwhile, the company has become profitable.
New Risk • Feb 28New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (NT$951.3m market cap, or US$28.9m).
New Risk • Dec 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.6% average weekly change). Market cap is less than US$100m (NT$1.12b market cap, or US$34.3m).
Valuation Update With 7 Day Price Move • Dec 23Investor sentiment improves as stock rises 17%After last week's 17% share price gain to NT$13.85, the stock trades at a trailing P/E ratio of 17.3x. Average trailing P/E is 18x in the Medical Equipment industry in Taiwan. Total loss to shareholders of 5.1% over the past three years.
Reported Earnings • Apr 12Full year 2023 earnings released: EPS: NT$0.48 (vs NT$0.079 in FY 2022)Full year 2023 results: EPS: NT$0.48 (up from NT$0.079 in FY 2022). Revenue: NT$194.8m (up 6.8% from FY 2022). Net income: NT$38.1m (up 500% from FY 2022). Profit margin: 20% (up from 3.5% in FY 2022). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 108% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
공시 • Apr 03MicroBase Technology Corp., Annual General Meeting, Jun 24, 2024MicroBase Technology Corp., Annual General Meeting, Jun 24, 2024.
New Risk • Mar 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.6% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (NT$1.01b market cap, or US$31.8m).
New Risk • Aug 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (8.9% average weekly change). Minor Risk Market cap is less than US$100m (NT$1.12b market cap, or US$35.3m).
Reported Earnings • Apr 01Full year 2022 earnings released: EPS: NT$0.08 (vs NT$0.47 loss in FY 2021)Full year 2022 results: EPS: NT$0.08 (up from NT$0.47 loss in FY 2021). Revenue: NT$182.3m (down 14% from FY 2021). Net income: NT$6.35m (up NT$43.7m from FY 2021). Profit margin: 3.5% (up from net loss in FY 2021). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • Aug 15First half 2022 earnings released: NT$0.03 loss per share (vs NT$0.11 loss in 1H 2021)First half 2022 results: NT$0.03 loss per share (up from NT$0.11 loss in 1H 2021). Revenue: NT$82.9m (down 26% from 1H 2021). Net loss: NT$2.17m (loss narrowed 75% from 1H 2021). Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 13% per year.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • Aug 18First half 2021 earnings released: NT$0.11 loss per share (vs NT$0.41 loss in 1H 2020)The company reported a decent first half result with reduced losses and improved control over expenses, although revenues were weaker. First half 2021 results: Revenue: NT$111.6m (down 9.0% from 1H 2020). Net loss: NT$8.84m (loss narrowed 71% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.
분석 기사 • Apr 11Is MicroBase Technology (GTSM:3184) Using Debt In A Risky Way?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Reported Earnings • Apr 11Full year 2020 earnings released: NT$0.95 loss per share (vs NT$0.75 loss in FY 2019)The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: NT$249.8m (down 5.9% from FY 2019). Net loss: NT$74.0m (loss widened 51% from FY 2019). Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Feb 01New 90-day low: NT$12.75The company is down 34% from its price of NT$19.45 on 03 November 2020. The Taiwanese market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 26% over the same period.
Is New 90 Day High Low • Jan 15New 90-day low: NT$14.70The company is down 25% from its price of NT$19.50 on 16 October 2020. The Taiwanese market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 29% over the same period.
Is New 90 Day High Low • Dec 22New 90-day low: NT$16.20The company is down 16% from its price of NT$19.40 on 24 September 2020. The Taiwanese market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 13% over the same period.
Is New 90 Day High Low • Dec 05New 90-day low: NT$17.45The company is down 9.0% from its price of NT$19.10 on 04 September 2020. The Taiwanese market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 9.0% over the same period.
분석 기사 • Dec 01Is MicroBase Technology (GTSM:3184) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Is New 90 Day High Low • Nov 06New 90-day low: NT$18.90The company is down 8.0% from its price of NT$20.55 on 07 August 2020. The Taiwanese market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is down 4.0% over the same period.
Is New 90 Day High Low • Sep 22New 90-day low: NT$19.00The company is down 7.0% from its price of NT$20.50 on 24 June 2020. The Taiwanese market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 2.0% over the same period.